On May 17, 2022 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the 2022 H.C. Wainwright Global Investment Conference (Press release, Precigen, MAY 17, 2022, https://www.prnewswire.com/news-releases/precigen-to-participate-in-the-2022-hc-wainwright-global-investment-conference-301549528.html [SID1234614772]). A webcast of the event will be available beginning at 7:00 AM ET on Tuesday, May 24, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Participants may register and access the webcast through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.